Trial Profile
Efficacy and safety of apatinib in patient with relapse or refractory non-hodgkin lymphoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.